Open main menu

Oldest pages

Showing below up to 250 results in range #351 to #600.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Neurovascular syndrome‏‎ (13:15, 13 September 2019)
  2. Non-sphericity parameter‏‎ (13:16, 13 September 2019)
  3. Nuclear track detectors‏‎ (13:17, 13 September 2019)
  4. Particle radiance‏‎ (13:28, 13 September 2019)
  5. Peak skin dose‏‎ (13:28, 13 September 2019)
  6. Pelagic‏‎ (13:29, 13 September 2019)
  7. Percutaneous coronary intervention‏‎ (13:29, 13 September 2019)
  8. Pericarditis‏‎ (13:29, 13 September 2019)
  9. Pharynx‏‎ (13:30, 13 September 2019)
  10. Planned exposure situation‏‎ (13:30, 13 September 2019)
  11. Platelet-derived growth factor‏‎ (13:30, 13 September 2019)
  12. Practical radiological protection culture‏‎ (13:32, 13 September 2019)
  13. Prevailing circumstances‏‎ (13:32, 13 September 2019)
  14. Principle of application of dose limits‏‎ (13:32, 13 September 2019)
  15. Principle of justification‏‎ (13:33, 13 September 2019)
  16. Principle of optimisation‏‎ (13:33, 13 September 2019)
  17. Procedural values‏‎ (13:34, 13 September 2019)
  18. Progenitor cell‏‎ (13:35, 13 September 2019)
  19. Projected dose‏‎ (13:36, 13 September 2019)
  20. Protection strategy‏‎ (13:37, 13 September 2019)
  21. Protective action‏‎ (13:37, 13 September 2019)
  22. Protective action guide‏‎ (13:38, 13 September 2019)
  23. Public exposure‏‎ (13:39, 13 September 2019)
  24. Radiation modifier‏‎ (13:41, 13 September 2019)
  25. Radiation safety officer‏‎ (13:42, 13 September 2019)
  26. Radiation worker‏‎ (13:44, 13 September 2019)
  27. Radioactive dispersion device‏‎ (13:44, 13 September 2019)
  28. Radioactive source‏‎ (13:45, 13 September 2019)
  29. Radioactive substance‏‎ (13:46, 13 September 2019)
  30. Radioactivity‏‎ (13:46, 13 September 2019)
  31. Radiofrequency ablation‏‎ (13:46, 13 September 2019)
  32. Radiographer‏‎ (13:48, 13 September 2019)
  33. Radiological protection principles‏‎ (13:49, 13 September 2019)
  34. Radionuclides of natural origin‏‎ (13:49, 13 September 2019)
  35. Radioresponsiveness‏‎ (13:49, 13 September 2019)
  36. Radiosensitiser‏‎ (13:50, 13 September 2019)
  37. Radiosensitivity, cellular‏‎ (13:50, 13 September 2019)
  38. Reasonableness‏‎ (13:50, 13 September 2019)
  39. Recovery‏‎ (13:51, 13 September 2019)
  40. Recovery responder‏‎ (13:51, 13 September 2019)
  41. Reference bioassay function‏‎ (13:51, 13 September 2019)
  42. Reference biokinetic model‏‎ (13:52, 13 September 2019)
  43. Reference level‏‎ (13:52, 13 September 2019)
  44. Rehabilitation of living conditions‏‎ (13:52, 13 September 2019)
  45. Relocation‏‎ (13:53, 13 September 2019)
  46. Remedial action‏‎ (13:53, 13 September 2019)
  47. Remediation‏‎ (13:53, 13 September 2019)
  48. Repopulation‏‎ (13:54, 13 September 2019)
  49. Representative organism (non-human biota)‏‎ (13:54, 13 September 2019)
  50. Representative person‏‎ (13:54, 13 September 2019)
  51. Reproductive integrity‏‎ (13:55, 13 September 2019)
  52. Residual dose‏‎ (13:55, 13 September 2019)
  53. Respiratory protection‏‎ (13:55, 13 September 2019)
  54. Retrievability‏‎ (13:56, 13 September 2019)
  55. Reversibility‏‎ (13:56, 13 September 2019)
  56. Right to know‏‎ (13:57, 13 September 2019)
  57. Rigidity‏‎ (13:58, 13 September 2019)
  58. Routine monitoring‏‎ (13:58, 13 September 2019)
  59. Safety case‏‎ (13:59, 13 September 2019)
  60. Safety culture‏‎ (13:59, 13 September 2019)
  61. Scintigraphy‏‎ (13:59, 13 September 2019)
  62. Self-help protection‏‎ (14:00, 13 September 2019)
  63. Slow repair‏‎ (14:01, 13 September 2019)
  64. Solar cosmic radiation‏‎ (14:01, 13 September 2019)
  65. Solar cycle‏‎ (14:01, 13 September 2019)
  66. Solar particle event‏‎ (14:01, 13 September 2019)
  67. Source term‏‎ (14:02, 13 September 2019)
  68. Source-related‏‎ (14:02, 13 September 2019)
  69. South Atlantic anomaly‏‎ (14:03, 13 September 2019)
  70. Special (non-routine) monitoring‏‎ (14:03, 13 September 2019)
  71. Spontaneous fission‏‎ (14:03, 13 September 2019)
  72. Stakeholder‏‎ (14:04, 13 September 2019)
  73. Stenosis‏‎ (14:04, 13 September 2019)
  74. Storage‏‎ (14:04, 13 September 2019)
  75. Subcutaneous tissue‏‎ (14:05, 13 September 2019)
  76. Substantial radiation dose level‏‎ (14:05, 13 September 2019)
  77. Systemic model‏‎ (14:06, 13 September 2019)
  78. Tachycardia‏‎ (14:10, 13 September 2019)
  79. Target region‏‎ (14:10, 13 September 2019)
  80. Target tissue‏‎ (14:10, 13 September 2019)
  81. Telangiectasia‏‎ (14:11, 13 September 2019)
  82. Threshold dose for tissue reactions‏‎ (14:11, 13 September 2019)
  83. Thyroid blocking‏‎ (14:11, 13 September 2019)
  84. Time factor‏‎ (14:11, 13 September 2019)
  85. Tissue equivalent material‏‎ (14:12, 13 September 2019)
  86. Tolerability‏‎ (14:12, 13 September 2019)
  87. Track structure‏‎ (14:13, 13 September 2019)
  88. Transfer compartment‏‎ (14:14, 13 September 2019)
  89. Transfer rate‏‎ (14:14, 13 September 2019)
  90. Transforming growth factor‏‎ (14:15, 13 September 2019)
  91. Transparency‏‎ (14:15, 13 September 2019)
  92. Trapped particles‏‎ (14:16, 13 September 2019)
  93. Types of materials‏‎ (14:16, 13 September 2019)
  94. Application of ionising radiation in healthcare (old)‏‎ (18:00, 9 October 2019)
  95. Information for patients, family members, carers and the public (old)‏‎ (18:00, 9 October 2019)
  96. Information for healthcare providers (old)‏‎ (18:00, 9 October 2019)
  97. Application of ionising radiation in healthcare‏‎ (18:04, 9 October 2019)
  98. Information for patients, family members, carers and the public‏‎ (18:11, 9 October 2019)
  99. Information for healthcare providers‏‎ (18:21, 9 October 2019)
  100. ICRPædia Guides‏‎ (18:33, 9 October 2019)
  101. List of ICRP Publications on Radiological Protection in Healthcare‏‎ (13:57, 17 October 2019)
  102. Guide to Radiological Protection in Healthcare‏‎ (13:59, 17 October 2019)
  103. The System of Radiological Protection‏‎ (15:15, 23 October 2019)
  104. Quotes from Publications on the System of Radiological Protection‏‎ (17:58, 23 October 2019)
  105. Guide to the System of Radiological Protection‏‎ (15:40, 24 October 2019)
  106. General Information on Radon‏‎ (12:41, 30 October 2019)
  107. System Of Radiation Protection Overview‏‎ (15:02, 4 November 2019)
  108. System of radiation protection module 2‏‎ (15:11, 4 November 2019)
  109. Absorbed, Equivalent, and Effective Dose‏‎ (21:54, 21 November 2019)
  110. Radon For Governments and Employers‏‎ (18:19, 3 December 2019)
  111. Radon For Homeowners and Residents‏‎ (18:19, 3 December 2019)
  112. Guide to Radon‏‎ (07:37, 5 February 2020)
  113. Main Page‏‎ (12:31, 18 November 2020)
  114. Additive risk projection model‏‎ (20:28, 24 February 2021)
  115. Attributable risk‏‎ (20:30, 24 February 2021)
  116. Dicentric chromosome‏‎ (20:31, 24 February 2021)
  117. Effect modifier‏‎ (20:32, 24 February 2021)
  118. Hereditary effect‏‎ (20:33, 24 February 2021)
  119. Low dose‏‎ (20:33, 24 February 2021)
  120. Low dose rate‏‎ (20:35, 24 February 2021)
  121. Multiplicative risk projection model‏‎ (20:36, 24 February 2021)
  122. Ring chromosome‏‎ (20:38, 24 February 2021)
  123. Severe deterministic injury‏‎ (20:38, 24 February 2021)
  124. Somatic effect‏‎ (20:39, 24 February 2021)
  125. Transgenerational effect‏‎ (20:40, 24 February 2021)
  126. Detriment-adjusted risk‏‎ (20:42, 24 February 2021)
  127. Elemental dose‏‎ (20:44, 24 February 2021)
  128. Multistage carcinogenesis model‏‎ (20:50, 24 February 2021)
  129. Mutation component‏‎ (20:51, 24 February 2021)
  130. Oncogene‏‎ (20:52, 24 February 2021)
  131. Population risk‏‎ (20:53, 24 February 2021)
  132. Potentially lethal damage repair‏‎ (20:54, 24 February 2021)
  133. Radiation risk‏‎ (20:55, 24 February 2021)
  134. Relative life lost‏‎ (20:56, 24 February 2021)
  135. Risk model‏‎ (20:57, 24 February 2021)
  136. Sublethal damage repair‏‎ (20:58, 24 February 2021)
  137. Transfer of risk‏‎ (20:59, 24 February 2021)
  138. Tumour suppressor gene‏‎ (21:00, 24 February 2021)
  139. Acute radiation syndrome‏‎ (21:40, 24 February 2021)
  140. Adaptive response‏‎ (21:42, 24 February 2021)
  141. Α/β value‏‎ (21:46, 24 February 2021)
  142. ΓH2AX foci‏‎ (21:46, 24 February 2021)
  143. Informed consent‏‎ (21:49, 24 February 2021)
  144. Supervised area‏‎ (21:51, 24 February 2021)
  145. Access control‏‎ (21:52, 24 February 2021)
  146. Acute exposure‏‎ (21:54, 24 February 2021)
  147. Adventitious source‏‎ (21:55, 24 February 2021)
  148. Authorised discharge‏‎ (21:57, 24 February 2021)
  149. Backscatter factor‏‎ (21:59, 24 February 2021)
  150. Best available techniques‏‎ (22:00, 24 February 2021)
  151. Disposal facility‏‎ (22:02, 24 February 2021)
  152. Dose modifying factor‏‎ (22:03, 24 February 2021)
  153. Exposure pathway‏‎ (22:05, 24 February 2021)
  154. Radiological controlled area‏‎ (22:07, 24 February 2021)
  155. Life Span Study‏‎ (22:10, 24 February 2021)
  156. Detriment‏‎ (19:17, 25 February 2021)
  157. Baseline disease rates‏‎ (19:29, 25 February 2021)
  158. Biomarker‏‎ (19:31, 25 February 2021)
  159. Case–control study‏‎ (19:33, 25 February 2021)
  160. Deterministic effect‏‎ (19:38, 25 February 2021)
  161. Dose and dose-rate effectiveness factor‏‎ (15:54, 26 February 2021)
  162. Dose-threshold hypothesis‏‎ (15:56, 26 February 2021)
  163. Tissue reaction‏‎ (16:00, 26 February 2021)
  164. Doubling dose‏‎ (17:10, 26 February 2021)
  165. Epigenetic effects‏‎ (17:13, 26 February 2021)
  166. Excess absolute risk‏‎ (17:16, 26 February 2021)
  167. Excess relative risk‏‎ (17:25, 26 February 2021)
  168. Homologous recombination‏‎ (17:26, 26 February 2021)
  169. Incidence‏‎ (17:28, 26 February 2021)
  170. Induced genomic instability‏‎ (17:30, 26 February 2021)
  171. Late normal tissue responses‏‎ (17:31, 26 February 2021)
  172. LD 50/30‏‎ (17:33, 26 February 2021)
  173. Lifetime risk estimates‏‎ (17:42, 26 February 2021)
  174. Linear dose response‏‎ (17:43, 26 February 2021)
  175. Linear-quadratic dose response model‏‎ (17:48, 26 February 2021)
  176. Stochastic effect‏‎ (17:58, 26 February 2021)
  177. Nominal risk coefficient‏‎ (19:29, 26 February 2021)
  178. Non-homologous end joining‏‎ (19:30, 26 February 2021)
  179. Non-targeted effects‏‎ (19:31, 26 February 2021)
  180. Normal tissue complication probability‏‎ (19:33, 26 February 2021)
  181. Pooled analysis‏‎ (19:34, 26 February 2021)
  182. Quasi-threshold dose‏‎ (19:35, 26 February 2021)
  183. Reactive oxygen species‏‎ (19:36, 26 February 2021)
  184. Recovery (cellular or tissue)‏‎ (19:38, 26 February 2021)
  185. Reference Animal and Plant‏‎ (19:43, 26 February 2021)
  186. Relative biological effectiveness‏‎ (20:22, 26 February 2021)
  187. Relative risk‏‎ (20:25, 26 February 2021)
  188. Risk coefficient‏‎ (20:30, 26 February 2021)
  189. Targeted effects‏‎ (20:32, 26 February 2021)
  190. Translocation‏‎ (20:33, 26 February 2021)
  191. Radiation source‏‎ (21:04, 26 February 2021)
  192. Dose-response function‏‎ (14:57, 28 March 2021)
  193. Tissue weighting factor‏‎ (21:32, 28 March 2021)
  194. Absorption‏‎ (22:15, 28 March 2021)
  195. Activation‏‎ (22:16, 28 March 2021)
  196. Activity‏‎ (22:19, 28 March 2021)
  197. ICRPædia Guide to the System of Radiological Protection‏‎ (21:44, 3 May 2021)
  198. Active detection system‏‎ (19:35, 11 August 2021)
  199. Additional dose‏‎ (19:36, 11 August 2021)
  200. Allometry‏‎ (19:37, 11 August 2021)
  201. Commissioning‏‎ (19:42, 11 August 2021)
  202. Compartment (environmental)‏‎ (19:44, 11 August 2021)
  203. Accreditation‏‎ (19:45, 11 August 2021)
  204. Backscatter detection system‏‎ (19:48, 11 August 2021)
  205. Clearance‏‎ (19:50, 11 August 2021)
  206. Concentration ratio‏‎ (19:52, 11 August 2021)
  207. Containment‏‎ (19:56, 11 August 2021)
  208. Cosmic radiation‏‎ (19:57, 11 August 2021)
  209. Derived reference level‏‎ (20:00, 11 August 2021)
  210. Derived limit‏‎ (20:00, 11 August 2021)
  211. Derived consideration reference level‏‎ (20:02, 11 August 2021)
  212. Designated area‏‎ (20:03, 11 August 2021)
  213. Evacuation‏‎ (20:07, 11 August 2021)
  214. Exclusion‏‎ (20:08, 11 August 2021)
  215. Exposed individuals‏‎ (20:09, 11 August 2021)
  216. Frequent flyer‏‎ (20:11, 11 August 2021)
  217. Ground-level enhancement‏‎ (20:12, 11 August 2021)
  218. ICRU 4-element tissue‏‎ (20:14, 11 August 2021)
  219. ICRU sphere‏‎ (20:17, 11 August 2021)
  220. Intervention‏‎ (20:18, 11 August 2021)
  221. Licensee‏‎ (20:20, 11 August 2021)
  222. National radon survey‏‎ (20:20, 11 August 2021)
  223. Nominal value‏‎ (20:21, 11 August 2021)
  224. Occupancy factor‏‎ (20:22, 11 August 2021)
  225. Operating management‏‎ (20:23, 11 August 2021)
  226. Potential exposure‏‎ (23:17, 11 August 2021)
  227. Collective dose‏‎ (23:18, 11 August 2021)
  228. Optimisation of protection‏‎ (23:22, 11 August 2021)
  229. Practice‏‎ (23:25, 11 August 2021)
  230. Principles of protection‏‎ (23:25, 11 August 2021)
  231. Radioactive waste‏‎ (23:29, 11 August 2021)
  232. Radiological attack‏‎ (23:30, 11 August 2021)
  233. Radon progeny‏‎ (23:30, 11 August 2021)
  234. Radon-prone area‏‎ (23:31, 11 August 2021)
  235. Redox‏‎ (23:31, 11 August 2021)
  236. Reference value‏‎ (23:34, 11 August 2021)
  237. Safety‏‎ (23:36, 11 August 2021)
  238. Region‏‎ (23:36, 11 August 2021)
  239. Sealed source‏‎ (23:38, 11 August 2021)
  240. Solar flare‏‎ (23:59, 11 August 2021)
  241. Sheltering‏‎ (00:00, 12 August 2021)
  242. Security‏‎ (00:01, 12 August 2021)
  243. Security screening‏‎ (00:02, 12 August 2021)
  244. Protection quantities‏‎ (14:51, 12 August 2021)
  245. Source-related assessment‏‎ (14:53, 12 August 2021)
  246. Superposition principle‏‎ (14:55, 12 August 2021)
  247. Surface contamination‏‎ (14:56, 12 August 2021)
  248. Thoron progeny‏‎ (14:57, 12 August 2021)
  249. Transmission detection system‏‎ (14:59, 12 August 2021)
  250. Trophic level‏‎ (15:00, 12 August 2021)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)